Trial intelligence / Profile preview

Capmatinib + Osimertinib vs Platinum–Pemetrexed in MET-amplified EGFR-mutant NSCLC

CTR20213106Phase 3Terminated

Sponsor

Novartis

Start

Dec 2021

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules

Countries

1